Tech Company Financing Transactions

EIP Pharma Funding Round

EIP Pharma closed a $20.5 million Series B financing round on 5/17/2018. Investors included Access Industries and private investors.

Transaction Overview

Company Name
Announced On
5/17/2018
Transaction Type
Venture Equity
Amount
$20,500,000
Round
Series B
Investors

Access Industries (Lead Investor)

Proceeds Purpose
Proceeds from the financing will be used to further advance development of neflamapimod, an oral small molecule inhibitor of the intra-cellular enzyme p38 MAP kinase alpha (p38 alpha) being studied in Alzheimer's disease.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
120 St. James Ave. 6th Floor The Yard 6017
Boston, MA 02116
USA
Email Address
Not Recorded
Overview
EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer's disease.
Profile
EIP Pharma LinkedIn Company Profile
Social Media
EIP Pharma Company Twitter Account
Company News
EIP Pharma News
Facebook
EIP Pharma on Facebook
YouTube
EIP Pharma on YouTube

Management Team

Title
Name
Email & Social
Chairman
Sylvie Grégoire
  Sylvie Grégoire LinkedIn Profile  Sylvie Grégoire Twitter Account  Sylvie Grégoire News  Sylvie Grégoire on Facebook
Chief Executive Officer
John Alam
  John Alam LinkedIn Profile  John Alam Twitter Account  John Alam News  John Alam on Facebook
VP - Bus. Development
Kelly Blackburn
  Kelly Blackburn LinkedIn Profile  Kelly Blackburn Twitter Account  Kelly Blackburn News  Kelly Blackburn on Facebook
VP - Bus. Development
Darryl Patrick
  Darryl Patrick LinkedIn Profile  Darryl Patrick Twitter Account  Darryl Patrick News  Darryl Patrick on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/17/2018: HiFiBiO Therapeutics venture capital transaction
Next: 5/17/2018: Lulus venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary